Takeda Pharmaceutical (TAK) Long-Term Debt Issuances (2018 - 2026)

Takeda Pharmaceutical's Long-Term Debt Issuances history runs 9 years deep, the most recent figure standing at $3.6 billion for Q1 2026.

• On a quarterly basis, Long-Term Debt Issuances fell 46.25% year-over-year to $3.6 billion in Q1 2026; TTM through Mar 2026 was $3.7 billion, a 44.34% decrease from a year earlier, with the FY2026 full-year figure at $3.9 billion, down 42.11% from the prior year.
• Long-Term Debt Issuances improved to $3.6 billion in Q1 2026 per TAK's latest filing, from $130.4 million in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $6.8 billion in Q1 2025 and bottomed at -$341.4 million in Q2 2022.
• The 5-year median for Long-Term Debt Issuances is $82.9 million (2025), against an average of $838.9 million.
• Across the five-year window, Long-Term Debt Issuances tumbled 386.63% in 2024 and surged 813.02% in 2025, its largest moves.
• Year by year, Long-Term Debt Issuances stood at $284.3 million in 2022, then plunged by 205.17% to -$299.0 million in 2023, then soared by 117.29% to $51.7 million in 2024, then soared by 152.25% to $130.4 million in 2025, then soared by 2693.66% to $3.6 billion in 2026.
• Per Business Quant, the three latest TAK Long-Term Debt Issuances figures stand at $3.6 billion (Q1 2026), $130.4 million (Q4 2025), and $82.9 million (Q3 2025).